<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE root>
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" article-type="research-article" dtd-version="1.2" xml:lang="en"><front><journal-meta><journal-id journal-id-type="publisher-id">Perm Medical Journal</journal-id><journal-title-group><journal-title xml:lang="en">Perm Medical Journal</journal-title><trans-title-group xml:lang="ru"><trans-title>Пермский медицинский журнал (сетевое издание "Perm medical journal")</trans-title></trans-title-group></journal-title-group><issn publication-format="print">0136-1449</issn><issn publication-format="electronic">2687-1408</issn><publisher><publisher-name xml:lang="en">Eco-Vector</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="publisher-id">501764</article-id><article-id pub-id-type="doi">10.17816/pmj405100-109</article-id><article-categories><subj-group subj-group-type="toc-heading" xml:lang="en"><subject>Preventive and social medicine</subject></subj-group><subj-group subj-group-type="toc-heading" xml:lang="ru"><subject>Профилактическая и социальная медицина</subject></subj-group><subj-group subj-group-type="article-type"><subject>Research Article</subject></subj-group></article-categories><title-group><article-title xml:lang="en">Epidemiological characteristics of hepatitis c infection in Nizhny Novgorod at the first stage of infection control program (2016–2021)</article-title><trans-title-group xml:lang="ru"><trans-title>Эпидемиологическая характеристика гепатита с в Нижегородском регионе на первом этапе программы по борьбе с инфекцией (2016–2021 гг.)</trans-title></trans-title-group></title-group><contrib-group><contrib contrib-type="author"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0001-9893-5848</contrib-id><contrib-id contrib-id-type="spin">6002-8194</contrib-id><name-alternatives><name xml:lang="en"><surname>Kashnikova</surname><given-names>A. D.</given-names></name><name xml:lang="ru"><surname>Кашникова</surname><given-names>А. Д.</given-names></name></name-alternatives><address><country country="RU">Russian Federation</country></address><bio xml:lang="en"><p>researcher, Laboratory of Epidemiology and Viral Hepatites</p></bio><bio xml:lang="ru"><p>научный сотрудник лаборатории эпидемиологии вирусных гепатитов</p></bio><email>gabckad@gmail.com</email><xref ref-type="aff" rid="aff1"/></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0003-1258-5467</contrib-id><contrib-id contrib-id-type="scopus">57194604102</contrib-id><contrib-id contrib-id-type="spin">8245-4909</contrib-id><name-alternatives><name xml:lang="en"><surname>Polyanina</surname><given-names>A. V.</given-names></name><name xml:lang="ru"><surname>Полянина</surname><given-names>А. В.</given-names></name></name-alternatives><address><country country="RU">Russian Federation</country></address><bio xml:lang="en"><p>Candidate of Medical Sciences, Leading Researcher, Head of the Laboratory of Epidemiology and Viral Hepatites</p></bio><bio xml:lang="ru"><p>кандидат медицинских наук, ведущий научный сотрудник – заведующий лабораторией эпидемиологии вирусных гепатитов</p></bio><email>polyanina.anastasia@yandex.ru</email><xref ref-type="aff" rid="aff1"/></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0001-5370-4026</contrib-id><contrib-id contrib-id-type="scopus">7101903242</contrib-id><name-alternatives><name xml:lang="en"><surname>Zaitseva</surname><given-names>N. N.</given-names></name><name xml:lang="ru"><surname>Зайцева</surname><given-names>Н. Н.</given-names></name></name-alternatives><address><country country="RU">Russian Federation</country></address><bio xml:lang="en"><p>MD, PhD, Director</p></bio><bio xml:lang="ru"><p>доктор медицинских наук, директор</p></bio><email>micro@nniiem.ru</email><xref ref-type="aff" rid="aff1"/></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0002-2719-6328</contrib-id><contrib-id contrib-id-type="scopus">57225802197</contrib-id><name-alternatives><name xml:lang="en"><surname>Bystrova</surname><given-names>T. N.</given-names></name><name xml:lang="ru"><surname>Быстрова</surname><given-names>Т. Н.</given-names></name></name-alternatives><address><country country="RU">Russian Federation</country></address><bio xml:lang="en"><p>MD, PhD, Professor, Leading Researcher, Laboratory of Epidemiology and Viral Hepatites</p></bio><bio xml:lang="ru"><p>доктор медицинских наук, профессор, ведущий научный сотрудник лаборатории эпидемиологии вирусных гепатитов</p></bio><email>gepatit-bystrova@yandex.ru</email><xref ref-type="aff" rid="aff1"/></contrib></contrib-group><aff-alternatives id="aff1"><aff><institution xml:lang="en">Academician I.N. Blokhina Nizhny Novgorod Scientific Research Institute of Epidemiology and Microbiology</institution></aff><aff><institution xml:lang="ru">Нижегородский научно-исследовательский институт эпидемиологии и микробиологии им. академика И.Н. Блохиной Роспотребнадзора</institution></aff></aff-alternatives><pub-date date-type="pub" iso-8601-date="2023-10-18" publication-format="electronic"><day>18</day><month>10</month><year>2023</year></pub-date><volume>40</volume><issue>5</issue><issue-title xml:lang="en"/><issue-title xml:lang="ru"/><fpage>100</fpage><lpage>109</lpage><history><date date-type="received" iso-8601-date="2023-06-22"><day>22</day><month>06</month><year>2023</year></date></history><permissions><copyright-statement xml:lang="en">Copyright ©; 2023, Eco-Vector</copyright-statement><copyright-statement xml:lang="ru">Copyright ©; 2023, Эко-Вектор</copyright-statement><copyright-year>2023</copyright-year><copyright-holder xml:lang="en">Eco-Vector</copyright-holder><copyright-holder xml:lang="ru">Эко-Вектор</copyright-holder><ali:free_to_read xmlns:ali="http://www.niso.org/schemas/ali/1.0/"/></permissions><self-uri xlink:href="https://permmedjournal.ru/PMJ/article/view/501764">https://permmedjournal.ru/PMJ/article/view/501764</self-uri><abstract xml:lang="en"><p><bold>Objective.</bold> To characterize the peculiarities of the epidemic process of viral hepatitis C in Nizhny Novgorod at the first stage of the infection control program (2016–2021).</p> <p><bold>Materials and Methods.</bold> A retrospective analysis of the incidence of registered forms of HCV infection in Nizhny Novgorod was carried out using information of statistical and analytical materials. A total of 78 883 blood serum samples were collected from individuals undergoing pre-hospital screening and admitted to non-infectious hospitals from 2016 to 2021. Laboratory testing included the determination of HCV infection markers: anti-HCV IgM and IgG, antibodies to structural and non-structural proteins (<italic>n</italic> = 2953). Seropositive samples were tested for the presence of HCV RNA (<italic>n</italic> = 467) using the Real Time PCR method.</p> <p><bold>Results. </bold>A trend towards a decrease in the incidence of registered forms of HCV infection was observed in Nizhny Novgorod from 2016 to 2021. It was found that among the various suspected transmission routes and risk factors for HCV infection, the predominant ones were a history of injected drug used and sexual transmission. The seroprevalence of anti-HCV was 3.6 ± 0.1 % and the prevalence of HCV RNA among the adult population was 1.8 ± 0.1 %. The highest prevalence of active HCV infection was observed in the age groups of 30–39 years (3.3 ± 0.3 %) and 40–49 years (5.7 ± 0.5 %).</p> <p><bold>Conclusions.</bold> To achieve the goals of the HCV elimination program, targeted and dynamic seroepidemiological studies are necessary to increase the number of individuals screened for HCV infection markers, with subsequent expansion of access to effective antiviral therapy for those with active infection.</p></abstract><trans-abstract xml:lang="ru"><p><bold>Цель.</bold> Охарактеризовать особенности проявления эпидемического процесса вирусного гепатита С (ГС) в Нижегородском регионе на первом этапе программы по борьбе с инфекцией (2016–2021 гг.).</p> <p><bold>Материалы и методы.</bold> Ретроспективный анализ заболеваемости регистрируемыми формами ГС-инфекции на территории Н. Новгорода выполнен с использованием информационных сборников статистических и аналитических материалов Роспотребнадзора. Из банка сывороток крови отобрано 78 883 образца от лиц, проходивших обследование на догоспитальном этапе и при поступлении в стационары неинфекционного профиля с 2016 по 2021 г. Лабораторное исследование включало определение маркёров инфицирования вирусом гепатита С: анти-ВГС классов иммуноглобулинов M и G, антител к структурному и неструктурным белкам (<italic>n</italic> = 2953). Серопозитивные образцы исследованы на наличие геномной РНК ВГС (<italic>n</italic> = 467) методом ОТ-ПЦР в режиме Real-Time.</p> <p><bold>Результаты.</bold> В 2016–2021 гг. в Н. Новгороде установлена тенденция к снижению заболеваемости регистрируемыми формами гепатита С. Установлено, что среди ряда предполагаемых путей передачи и факторов риска заражения гепатитом С превалирующими являются употребление инъекционных наркотических средств в анамнезе и половой путь передачи. По результатам проведённого сероэпидемиологического исследования инцидентность анти-ВГС составила 3,6 ± 0,1 % Распространённость РНК ВГС среди взрослого населения – 1,8 ± 0,1 %, максимальных значений показатель распространенности маркёра текущей инфекции достигал в возрастных группах 30–39 лет (3,3 ± 0,3 %) и 40–49 лет (5,7 ± 0,5 %). Для достижения целей программы по борьбе с гепатитом С необходимо проведение целенаправленных динамических сероэпидемиологических исследований, позволяющих увеличить количество обследованных лиц на наличие маркёров ГС-инфекции с последующим расширением доступности и охвата эффективной противовирусной терапией лиц с активной инфекцией.</p></trans-abstract><kwd-group xml:lang="en"><kwd>hepatitis C</kwd><kwd>serological testing</kwd><kwd>molecular genetic testing</kwd><kwd>epidemiological surveillance</kwd><kwd>infection markers</kwd></kwd-group><kwd-group xml:lang="ru"><kwd>гепатит С</kwd><kwd>серологическое исследование</kwd><kwd>молекулярно-генетическое исследование</kwd><kwd>эпидемиологический надзор</kwd><kwd>маркёры инфицирования</kwd></kwd-group><funding-group/></article-meta></front><body></body><back><ref-list><ref id="B1"><label>1.</label><mixed-citation>WHO. Гепатит С, available at: https://www.who.int/ru/news-room/fact-sheets/detail/hepatitis-c.</mixed-citation></ref><ref id="B2"><label>2.</label><mixed-citation>Pol S., Lagaye S. The remarkable history of the hepatitis C virus. Genes and Immunity 2019; 20: 436–446.</mixed-citation></ref><ref id="B3"><label>3.</label><mixed-citation>Gower E., Estes C., Blach S. et al. Global epidemiology and genotype distribution of the hepatitis C virus infection. Journal of Hepatology 2014; 61: 45–57.</mixed-citation></ref><ref id="B4"><label>4.</label><mixed-citation>WHO Regional Office for Europe. Action plan for the health sector response to viral hepatitis in the WHO European Region. 2017; 5: 1–45.</mixed-citation></ref><ref id="B5"><label>5.</label><mixed-citation>Hatzakis A., Chulanov V., Gadano A.C. et al. The present and future disease burden of hepatitis C virus (HCV) infections with today’s treatment paradigm – Volume 2. Journal of Viral Hepatitis 2015; 22: 26–45.</mixed-citation></ref><ref id="B6"><label>6.</label><citation-alternatives><mixed-citation xml:lang="en">Han R., Zhou J., François C. et al. Preva-lence of hepatitis C infection among the general population and high-risk groups in the EU/EEA: A systematic review update. BMC Infectious Diseases 2019; 19: 1–14.</mixed-citation><mixed-citation xml:lang="ru">Han R., Zhou J., François C. et al. Prevalence of hepatitis C infection among the general population and high-risk groups in the EU/EEA: A systematic review update. BMC Infectious Diseases 2019; 19: 1–14.</mixed-citation></citation-alternatives></ref><ref id="B7"><label>7.</label><citation-alternatives><mixed-citation xml:lang="en">Maaroufi A., Vince A., Himatt S.M. et al. Historical epidemiology of hepatitis C vi-rus in select countries – volume 4. Journal of Viral Hepatitis 2017; 24: 8–24.</mixed-citation><mixed-citation xml:lang="ru">Maaroufi A., Vince A., Himatt S.M. et al. Historical epidemiology of hepatitis C virus in select countries – volume 4. Journal of Viral Hepatitis 2017; 24: 8–24.</mixed-citation></citation-alternatives></ref><ref id="B8"><label>8.</label><mixed-citation>Hofstraat S.H.I., Falla A.M., Duffell E.F. et al. Current prevalence of chronic hepatitis B and C virus infection in the general population, blood donors and pregnant women in the EU/EEA: A systematic review. Epidemiology and Infection 2017; 145: 2873–2885.</mixed-citation></ref><ref id="B9"><label>9.</label><citation-alternatives><mixed-citation xml:lang="en">Geneva: World Health Organization. Global health sector strategies on, respectively, HIV, viral hepatitis and sexually transmitted infections for the period 2022–2030. World Health Organization, Switzerland 2022; 134.</mixed-citation><mixed-citation xml:lang="ru">Geneva: World Health Organization. Global health sector strategies on, respectively, HIV, viral hepatitis and sexually transmitted infections for the period 2022–2030. World Health Organization. Switzerland 2022; 134.</mixed-citation></citation-alternatives></ref><ref id="B10"><label>10.</label><mixed-citation>Blach S., Terrault N.A., Tacke F. et al. Global change in hepatitis C virus prevalence and cascade of care between 2015 and 2020: a modelling study. The Lancet Gastroenterology &amp; Hepatology 2022; 7: 396–415.</mixed-citation></ref><ref id="B11"><label>11.</label><mixed-citation>Blach S., Zeuzem S., Manns M. et al. Global prevalence and genotype distribution of hepatitis C virus infection in 2015: A modelling study. The Lancet Gastroenterology and Hepatology 2017; 2: 161–176.</mixed-citation></ref><ref id="B12"><label>12.</label><citation-alternatives><mixed-citation xml:lang="en">List of instructions for the implementation of the Message of the President of the Russian Federation to the Federal Assembly of the Russian Federation dated April 21, 2021, available at: http://www.kremlin.ru/acts/assignments/orders/65524 (in Russian).</mixed-citation><mixed-citation xml:lang="ru">Перечень поручений по реализации Послания Президента Российской Федерации Федеральному Собранию Российской Федерации от 21 апреля 2021 года, available at: http://www.kremlin.ru/acts/assignments/orders/65524.</mixed-citation></citation-alternatives></ref><ref id="B13"><label>13.</label><citation-alternatives><mixed-citation xml:lang="en">Mikhaylov M.I., Yushchuk N.D., Malinnikova E.Yu., Kyuregyan K.K., Isaeva O.V., Znoyko О.О. Klimova E.A. Viral hepatitis as public health problem in the Russian Federation (a design program for the control and elimination of viral hepatitis). Healthcare Management: news, views, education. Bulletin of VSHOUZ 2018; 2: 20–29 (in Russian).</mixed-citation><mixed-citation xml:lang="ru">Михайлов М.И., Ющук Н.Д., Малинникова Е.Ю., Кюрегян К.К., Исаева О.В., Знойко О.О., Климова Е.А. Вирусные гепатиты – проблема общественного здоровья в Российской Федерации (проект программы по контролю и ликвидации вирусных гепатитов). Оргздрав: Новости, Мнения, Обучение. Вестник ВШОУЗ 2018; 2: 20–29.</mixed-citation></citation-alternatives></ref><ref id="B14"><label>14.</label><citation-alternatives><mixed-citation xml:lang="en">The action plan to combat hepatitis C, available at: http://government.ru/news/46972 (in Russian).</mixed-citation><mixed-citation xml:lang="ru">План мероприятий по борьбе с гепатитом С, available at: http://government.ru/news/46972</mixed-citation></citation-alternatives></ref><ref id="B15"><label>15.</label><citation-alternatives><mixed-citation xml:lang="en">Soboleva N.V., Carlsen A.A., Kozhanova T.V.et al. Frequency of detection of antibodies to hepatitis C virus among conventionally healthy population of Russian Federation. Zh. Mikrobiol. (Moscow). 2017; 3: 99–106 (in Russian).</mixed-citation><mixed-citation xml:lang="ru">Соболева H.В., Карлсен А.А., Кожанова Т.В. и др. Частота выявления антител к вирусу гепатита С среди условно здорового населения Российской Федерации. Журнал микробиологии 2017; 3: 99–106.</mixed-citation></citation-alternatives></ref><ref id="B16"><label>16.</label><citation-alternatives><mixed-citation xml:lang="en">Soboleva N.V. The prevalence of hepatitis C virus among the conditionally healthy population of the Russian Federation: abstract. dis. … cand. biol. sciences. Moscow 2020; 25 (in Russian).</mixed-citation><mixed-citation xml:lang="ru">Соболева Н.В. Распространенность вируса гепатита С среди условно здорового населения Российской Федерации: автореф. дис. … канд. биол. наук. М. 2020; 25.</mixed-citation></citation-alternatives></ref><ref id="B17"><label>17.</label><citation-alternatives><mixed-citation xml:lang="en">Yushchuk N.D., Znojko O.O., Yakushechkina N.A.et al. Assessment of the Socio-Economic Burden of Hepatitis C in the Russian Federation. Epidemiology and vaccinal prevention 2013; 2: 18–33 (in Russian).</mixed-citation><mixed-citation xml:lang="ru">Ющук Н.Д., Знойко О.О., Якушечкина Н.А. и др. Оценка социально-экономического бремени гепатита С в Российской Федерации. Эпидемиология и вакцинопрофилактика 2013; 2: 18–33.</mixed-citation></citation-alternatives></ref><ref id="B18"><label>18.</label><citation-alternatives><mixed-citation xml:lang="en">On the state of sanitary and epidemiological wellbeing of the population in the Russian Federation in 2022: State Report. Moscow: The Federal Service for the Oversight of Consumer Protection and Welfare 2023; 368 (in Russian).</mixed-citation><mixed-citation xml:lang="ru">О состоянии санитарно-эпидемиологического благополучия населения в Российской Федерации в 2022 г.: Государственный доклад. М.: Федеральная служба по надзору в сфере защиты прав потребителей и благополучия человека 2023; 368.</mixed-citation></citation-alternatives></ref></ref-list></back></article>
